Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID NAPRAPAC 250 COPACKAGED.
LANSOPRAZOLE vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateNaproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."